SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
&NA; The prevalence of type 2 diabetes mellitus (T2D) has risen in the United States and worldwide, with an increase in global prevalence from 4.7% to 8.5% between 1980 and 2014. A variety of antidiabetic drugs are available with different mechanisms of action, and multiple drugs are often used concomitantly to improve glycemic control. One of the newest classes of oral antihyperglycemic agents is the sodium glucose cotransporter‐2 (SGLT2) inhibitors or “flozins”. Recent clinical guidelines have suggested the use of SGLT2 inhibitors as add‐on therapy in patients for whom metformin alone does not achieve glycemic targets, or as initial dual therapy with metformin in patients who present with higher glycated hemoglobin (HbA1c) levels. The FDA has approved fixed‐dose combination (FDC) tablets with each of the three available SGLT2 inhibitors (canagliflozin, dapagliflozin, and empagliflozin) and metformin. Both drug classes are associated with the rare but serious life‐threatening complications that result from metabolic acidosis, including lactic acidosis (with metformin) and euglycemic diabetic ketoacidosis (with SGLT2 inhibitors). This review summarizes the current literature on the pharmacokinetics and the molecular targets of metformin and SGLT2 inhibitors. It also addresses the common adverse effects and highlights the molecular mechanisms by which this dual antihyperglycemic therapy contributes to high anion gap metabolic acidosis. In conclusion, while the combination of metformin and SGLT2 inhibitors would be a better option in improving glycemic control with a low risk of hypoglycemia, an increase in the risk of metabolic acidosis during combination therapy may be borne in mind.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AMPK: a nutrient and energy sensor that maintains energy homeostasis
Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3311 · Cited by 4,602
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157 · cited 4×
“…been shown to inhibit gluconeogenesis by the following mechanisms: i) inhibition of mitochondrial respiratory chain complex 1 (El-Mir et al., 2000; Owen et al., 2000); ii) inhibition of mitochondrial glycerophosphate dehydrogenase (mGPD) (Madiraju et al., 2014); iii) AMP-mediated inhibition of…”
InfluentialHyperglycemic crises in adult patients with diabetes
Kitabchi, A. E., Umpierrez, G. E., Miles, J. M., & Fisher, J. N. (2009) · Diabetes Care · doi:10.2337/dc09-9032 · Cited by 2,062
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
El-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399 · cited 1×
“, 2002), metformin has been shown to inhibit gluconeogenesis by the following mechanisms: i) inhibition of mitochondrial respiratory chain complex 1 (El-Mir et al., 2000; Owen et al., 2000); ii) inhibition of mitochondrial glycerophosphate dehydrogenase (mGPD) (Madiraju et al.”
Clinical pharmacokinetics of metformin
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11534750-000000000-00000 · Cited by 1,318 · cited 1×
“In contrast to the currently available metformin [immediate-release or extended-release formulation] that inhibits hepatic gluconeogenesis following its absorption through duodenum and jejunum (Graham et al., 2011), a recent study has shown that delayed-release metformin exhibits its antihyperglycemic effect predomina…”
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X.-M., Braddock, D. T., Albright, R. A., Prigaro, B. J., Wood, J. L., Bhanot, S., MacDonald, M. J., et al. (2014) · Nature · doi:10.1038/nature13270 · Cited by 1,284 · cited 4×
“, 2000); ii) inhibition of mitochondrial glycerophosphate dehydrogenase (mGPD) (Madiraju et al., 2014); iii) AMP-mediated inhibition of adenylyl cyclase (Miller et al.”
InfluentialForetz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181 · cited 2×
“, 2001); and v) AMPKindependent inhibition of glucose production (Foretz et al., 2010).”
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173 · cited 1×
“As shown in Table 2, the most common adverse effects of metformin are gastrointestinal in nature and include nausea, diarrhea, and abdominal discomfort (DeFronzo, 1999).”
Mechanism by which metformin reduces glucose production in type 2 diabetes.
Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052 · cited 1×
“The antihyperglycemic action of metformin is primarily attributed to its inhibitory effect on hepatic glucose output (Bailey and Turner, 1996; Hundal et al., 2000).”
Peters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849
Metformin and the gastrointestinal tract
McCreight, L. J., Bailey, C. J., & Pearson, E. R. (2016) · Diabetologia · doi:10.1007/s00125-015-3844-9 · Cited by 733 · cited 1×
“Although delayed-release metformin can enhance GLP-1 secretion/release from the intestinal L cells [cited in (McCreight et al., 2016; Henry et al., 2018)], the molecular mechanism by which it lowers blood glucose level remains unclear.”
Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670 · cited 2×
“In addition, SGLT2 inhibitor has been shown to inhibit SGLT2 protein expressed in the pancreatic α-cells, thereby enhancing glucagon release and hepatic gluconeogenesis (Bonner et al., 2015).”
Rosenstock, J., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-1380 · Cited by 664 · cited 3×
“Hyperglycemia (blood glucose> 250mg/dL) is a key component of DKA, with blood glucose upon presentation commonly up to 800mg/dL (Rosenstock and Ferrannini, 2015).”
InfluentialMetformin-associated lactic acidosis: current perspectives on causes and risk
DeFronzo, R., Fleming, G. A., Chen, K., & Bicsak, T. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.10.014 · Cited by 658 · cited 7×
“A more serious risk, although rare ( 10 cases per 100,000 patient-years), is metformin-associated lactic acidosis (MALA) (DeFronzo et al., 2016).”
InfluentialLong-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study
Aroda, V. R., Edelstein, S. L., Goldberg, R. B., Knowler, W. C., Marcovina, S. M., Orchard, T. J., Bray, G. A., Schade, D. S., Temprosa, M. G., White, N. H., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3754 · Cited by 536 · cited 2×
“In T2D, the increase in fasting plasma glucose concentration results from enhanced hepatic glucose output, which in turn is primarily due to increased gluconeogenesis in insulin-resistant state (Bailey and Turner, 1996).”
The Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1299 · Cited by 494
Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus
Watts, N. B., Bilezikian, J. P., Usiskin, K., Edwards, R., Desai, M., Law, G., & Meininger, G. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3167 · Cited by 454
Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin
Wang, D.-S., Jonker, J. W., Kato, Y., Kusuhara, H., Schinkel, A. H., & Sugiyama, Y. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034140 · Cited by 441 · cited 1×
“After its uptake through organic cation transporter-1 (Oct1) in hepatocytes (Wang et al., 2002), metformin has been shown to inhibit gluconeogenesis by the following mechanisms: i) inhibition of mitochondrial respiratory chain complex 1 (El-Mir et al.”
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435
Handelsman, Y., Henry, R. R., Bloomgarden, Z. T., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Ferrannini, E., Fonseca, V. A., Garber, A. J., Grunberger, G., et al. (2016) · Endocrine Practice · doi:10.4158/ep161292.ps · Cited by 358
Buse, J. B., DeFronzo, R. A., Rosenstock, J., Kim, T., Burns, C., Skare, S., Baron, A., & Fineman, M. (2016) · Diabetes Care · doi:10.2337/dc15-0488 · Cited by 325 · cited 4×
“…that inhibits hepatic gluconeogenesis following its absorption through duodenum and jejunum (Graham et al., 2011), a recent study has shown that delayed-release metformin exhibits its antihyperglycemic effect predominantly through its exposure in the lower gut (e.g., ileum) (Buse et al., 2016).”
InfluentialNeal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Ways, K., Desai, M., Shaw, W., Capuano, G., Alba, M., et al. (2015) · Diabetes Care · doi:10.2337/dc14-1237 · Cited by 233
Cited by
Type II diabetes mellitus: a review on recent drug based therapeutics.
Padhi, S., Nayak, A. K., & Behera, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110708 · Cited by 726
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Reuter, H.-M., & Siegel, E. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1018-9106 · Cited by 62
“Therefore, the DDG recommends, as does the ADA, that the following be considered when dealing with SGLT-2 inhibitors: ▪ SGLT-2 inhibitors must be discontinued 24 h prior to a major elective surgery, ▪ Immediate interruption of SGLT-2 inhibitor therapy in emergency cases and acute diseases, ▪ Caution during ongoing ins…”
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3449 · Cited by 12
Metadata
- Authors
- Donnan, K., & Segar, L.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 846
- Pages
- 23-29
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W2910786996
- Cited by
- 76
- References
- 24
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.